Gershon A A, Steinberg S P, Gelb L
Pediatrics. 1986 Oct;78(4 Pt 2):757-62.
Live attenuated varicella vaccine has been administered to 307 children with leukemia in remission and to 86 healthy adults. The vaccine was well tolerated and immunogenic. The major side effect in leukemic children receiving maintenance chemotherapy was development of a vaccine-associated rash. Vaccinees in whom a rash developed were potentially somewhat infectious to others about 1 month after immunization. Vaccination was not associated with an increase in the incidence of herpes zoster or in relapse of leukemia. Vaccination provided excellent protection against severe varicella. It was associated with a significant decrease in the attack rate of chickenpox following an intimate exposure to varicella-zoster virus, conferring about 80% protection in leukemic children. The cases of breakthrough varicella that occurred were mild. Thus, the vaccine may either prevent or modify varicella in high-risk individuals. It may also have use for prevention of nosocomial varicella.
减毒活水痘疫苗已接种于307名处于缓解期的白血病儿童和86名健康成人。该疫苗耐受性良好且具有免疫原性。接受维持化疗的白血病儿童的主要副作用是出现疫苗相关皮疹。出现皮疹的接种者在免疫后约1个月可能对他人有一定传染性。接种疫苗与带状疱疹发病率增加或白血病复发无关。接种疫苗为预防严重水痘提供了极佳的保护。在密切接触水痘带状疱疹病毒后，它与水痘发病率显著降低相关，为白血病儿童提供了约80%的保护。发生的突破性水痘病例症状较轻。因此，该疫苗可能预防或改变高危个体的水痘。它也可用于预防医院内水痘。
